• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011 - Product Image

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011

  • Published: August 2011
  • 103 pages
  • Global Markets Direct

Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011', provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury). 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Acute Renal Failure (ARF) (Acute Kidney Injury) Overview
Therapeutics Development
An Overview of Pipeline Products for Acute Renal Failure (ARF) (Acute Kidney Injury)
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Development by Companies
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Products under Development by Companies
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics Development
Quark Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
BioLineRx, Ltd.
FibroGen, Inc.
LEO Pharma A/S
Hadasit Medical Research Services & Development Ltd
NicOx SA
Theratechnologies Inc.
Torrent Pharmaceuticals Limited
Am-Pharma B.V.
Indus Biotech Private Limited
Angion Biomedica Corp.
Thrasos, Inc.
CorMedix, Inc.
Exponential Biotherapies, Inc.
Action Pharma A/S
Kringle Pharma, Inc.
Nephrx Corporation
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
FG-3019 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TH0673 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-4040 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LEO 27847 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bovine Alkaline Phosphatase (iv) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AA 184 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EA-230 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INDUS815B - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BB3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Naproxcinod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QPI 1002 (AKIi-5) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QPI 1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eculizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ChronSeal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Acetylcysteine + Deferoxamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bortezomib + Dexamethasone + Doxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acetylcysteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actos + Insulin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erythropoietin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP214 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Atorvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sodium Bicarbonate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Velcade + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Corlopam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sufrexal - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRMD-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erythropoietin Beta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epoetinum - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NX001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Bortezomib + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Curcumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fenoldopam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Furosemide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HYPER-IL-6 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fenoldopam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mesenchymal Stromal Cell Infusion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rasburicase - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HIF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics – Drug Profile Updates
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics - Discontinued Products
Acute Renal Failure (ARF) (Acute Kidney Injury) - Featured News
Aug 08, 2011: Final Patient Completes Last Visit In Action Pharma’s Phase IIb Clinical Trial Of Ap214
Jun 21, 2011: CorMedix Announces SPA Agreement With FDA For Phase III Trial Of CRMD001 Study In Prevention Of CI-AKI
May 09, 2011: Action Pharma Completes Dosing In Phase IIb Clinical Trial With AP214 To Prevent Acute Kidney Injury Undergoing Cardiac Surgery
Jul 06, 2010: Angion Biomedica Receives Fast Track And Orphan Drug Designations From FDA For BB3
Mar 10, 2010: AM-Pharma Presents Positive Results of Its Phase II Clinical Trial With Alkaline Phosphatase in Acute Kidney Injury At The ISICEM Conference In Brussels
Mar 10, 2010: Affymax Receives $5 Million Milestone Payment On Initiation Of Phase III Clinical Trials For Hematide In Japan
Feb 16, 2010: FDA Grants Orphan Drug Status for Quark’s QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients
Jan 05, 2010: Quark Pharmaceuticals To Advance Clinical Studies of QPI-1002
Nov 23, 2009: Proteon Initiates Second Phase 1/2 Clinical Study Of PRT-201 In Hemodialysis Patients
Nov 02, 2009: Quark Pharmaceuticals To Present Data On Its siRNA Therapeutic Programs In Kidney And Lung Diseases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2011
Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Quark Pharmaceuticals, Inc., 2011
Takeda Pharmaceutical Company Limited, 2011
BioLineRx, Ltd., 2011
FibroGen, Inc., 2011
LEO Pharma A/S, 2011
Hadasit Medical Research Services & Development Ltd, 2011
NicOx SA, 2011
Theratechnologies Inc., 2011
Torrent Pharmaceuticals Limited, 2011
Am-Pharma B.V., 2011
Indus Biotech Private Limited, 2011
Angion Biomedica Corp., 2011
Thrasos, Inc., 2011
CorMedix, Inc., 2011
Exponential Biotherapies, Inc., 2011
Action Pharma A/S, 2011
Kringle Pharma, Inc., 2011
Nephrx Corporation, 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Acute Renal Failure (ARF) (Acute Kidney Injury) Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H2 2011
Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury) – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos